Intelligene

Intelligene Stock-Based Compensation

The Stock-Based Compensation (SBC) of Intelligene (7832.TWO) as of Oct 20, 2026 is 42.16 M TWD. In the previous year, Stock-Based Compensation (SBC) was 5.16 M TWD — a change of 717.05% (higher).

Stock-Based Compensation

42.16 MTWD

YoY

717.05%

Last updated:

Stock-Based Compensation (SBC) of Intelligene is 2024 42.16 M TWD. Stock-Based Compensation (SBC) of Intelligene was 2023 5.16 M TWD. It decreases by 717.05% higher compared to the previous year.

The Intelligene Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2023
5.16 M TWD
Jan 1, 2024
42.16 M TWD
The Intelligene Stock-Based Compensation history
YEARStock-Based CompensationYoY
42.16 MTWD+717.05%
5.16 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Intelligene Stock analysis

What does Intelligene do? Intelligene Inc develops innovative RNA gene therapy drugs using siRNA gene compilation technology for treating pneumonia and influenza. The company focuses on research and development of nucleic acid drugs targeting all cases of pneumonia and influenza. Intelligene Inc is a Taiwan-based company with 20 full-time employees operating in the pharmaceutical industry. The company's primary revenue comes from the development and potential commercialization of its RNA-based gene therapy drugs. Intelligene Inc is engaged in the research and development of innovative nucleic acid drugs based on siRNA technology for pneumonia and influenza treatments. The firm aims to provide novel therapeutic solutions for respiratory diseases through its proprietary technology. Intelligene Inc's products target medical professionals and healthcare institutions seeking advanced treatments for pneumonia and influenza. The company's research focuses on developing drugs that address all cases of these respiratory conditions. The firm operates within the pharmaceutical sector with a specific emphasis on RNA-based therapies for respiratory illnesses. Intelligene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Intelligene stock

Stock-Based Compensation (SBC) of Intelligene is 42.16 M TWD in 2024.

Stock-Based Compensation (SBC) of Intelligene changed from 5.16 M TWD to 42.16 M TWD, representing a 717.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Intelligene since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Intelligene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Intelligene

All Key Metrics — Intelligene